| Abstract: | INTRODUCTION: MMPs are extracellular matrix (ECM)-degrading enzymes that play a crucial role in embryogenesis, tissue remodeling, inflammation and angiogenesis. MMP-2 and -9 (also called type 2 and type 4 collagenase, or gelatinase A and B) are the key molecules that control invasion, tumor growth and metastasis. Tissue inhibitor of matrix metalloproteinase (TIMP) -2 and -1 are specific inhibitors of MMP-2 and MMP-9 respectively, and play a crucial role in regulation of MMP-2 and -9 activation, during pathophysiological processes. MMPs can specifically degrade native gelatin, collagens, fibronectin, ectactin and elastin. MMP-2 and -9 are overexpressed in almost all types of cancers, and so act as important therapeutic targets. AREAS COVERED: The status of MMP research in India from 1998 to 2010. In this review, the authors cover the role of matrix metalloproteinase inhibitors in cancer therapy. EXPERT OPINION: As compared with other parts of the world, Indian scientists have not generated a significant number of specific MMP inhibitors for the treatment of cancer, or other diseases. MMPs and membrane type (MT)-MMPs are potentially important therapeutic targets in many diseases, including cancers, therefore, designing specific inhibitors from natural products or through synthetic routes, is crucial. |
